NCT01631227

Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension

A Prospective, Randomized Double-blind Parallel Group Study to Compare the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Subjects With Mild to Moderate Essential Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 665 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy. The new formulation is compared to the currently marketed eprosartan tablet. Equivalent efficacy in blood pressure lowering effects should be demonstrated.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Eprosartan	Eprosartan 450 mg
DRUG	Eprosartan Mesylate	Eprosartan mesylate 600 mg
DRUG	Placebo Eprosartan mesylate	Placebo Eprosartan mesylate
DRUG	Placebo Eprosartan	Placebo Eprosartan

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2012-06-29
• Last updated: 2014-07-25
• Results posted: 2014-05-26

Locations

38 sites across 3 countries: Germany, Russia, United Kingdom